Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

CG Oncology (CGON) Cost of Revenue (2025)

CG Oncology filings provide 1 years of Cost of Revenue readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a N/A change, with the full-year FY2025 number at $4.6 million, changed N/A from a year prior.
  • Cost of Revenue hit $3.1 million in Q4 2025 for CG Oncology, up from $1.6 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.1 million in Q4 2025 to a low of $1.6 million in Q3 2025.